Clinical Outcomes of Immunosuppressant Drugs in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Medical Principles and Practice · 18.06.2026 · 1-20
DOI: 10.1159/000553094 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Medical Principles and Practice, online erschienen am 18.06.2026. Verfasst von Faizah M Alotaibi und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, alotaibifai@ksau-hs.edu.sa. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
The aim of this study was to systematically evaluate the impact of immunosuppressant drugs (ISDs) use on clinical outcomes in patients with cancer treated with immune checkpoint inhibitors (ICIs).
Methods
A systematic review and meta-analysis was conducted. Eligible studies reporting overall survival (OS) and/or progression-free survival (PFS), among adult cancer patients receiving ICIs stratified by the use of ISDs.
Results
A total of 33 studies with 34,063 patients met the inclusion criteria. Pooled analyses showed significantly worse outcomes among patients receiving ISDs during ICI therapy, with poorer OS (HR = 1.31; 95% CI: 1.10–1.56; p = 0.003) and PFS (HR = 1.39; 95% CI: 1.10–1.76; p = 0.006) compared with those who did not receive ISDs with high heterogeneity of (I2 ∼ 80–85%). In subgroup analysis, patients with non-small-cell lung cancer exhibited significantly reduced OS associated with the use of ISDs.
Conclusions
The results suggest an association between ISDs use and reduced OS and PFS in patients with cancer receiving ICI treatment. These findings highlight the need for precision-based immune-related adverse events (irAEs) management strategies that balance toxicity control with preservation of therapeutic benefit.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, alotaibifai@ksau-hs.edu.sa.
- King Abdullah International Medical Research Center, Al-Ahsa, Saudi Arabia, alotaibifai@ksau-hs.edu.sa.
- Department of Oncology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia, alotaibifai@ksau-hs.edu.sa.
- King Abdullah International Medical Research Center, Al-Ahsa, Saudi Arabia.
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
- Department of Oncology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Zitieren
APA
Alotaibi, F. M., Alrowaydan, S. M., Alshamlani, L. K., Alomar, M. A., Almutairi, N. S., Khashwayn, S. A., Alshammari, K., & Al-Tawfiq, J. A. (2026). Clinical Outcomes of Immunosuppressant Drugs in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Medical Principles and Practice, 1-20. https://doi.org/10.1159/000553094
Vancouver
Alotaibi FM, Alrowaydan SM, Alshamlani LK, Alomar MA, Almutairi NS, Khashwayn SA, et al. Clinical Outcomes of Immunosuppressant Drugs in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Medical Principles and Practice. 2026:1-20. doi:10.1159/000553094
BibTeX
@article{Alotaibi2026,
author = {Alotaibi, Faizah M and Alrowaydan, Sara M and Alshamlani, Lamia K and Alomar, Manar A and Almutairi, Nora S and Khashwayn, Seham A and Alshammari, Kanan and Al-Tawfiq, Jaffar A},
title = {Clinical Outcomes of Immunosuppressant Drugs in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis},
journal = {Medical Principles and Practice},
year = {2026},
pages = {1--20},
doi = {10.1159/000553094}
}
EUVIMED